Mitral regurgitation resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(18 intermediate revisions by 2 users not shown)
Line 3: Line 3:


__NOTOC__
__NOTOC__
{{CMG}}; {{AE}} {{RT}}; {{M.P}}
{{CMG}}; {{AE}} {{M.P}}


{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0";
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0";
Line 27: Line 27:


==Overview==
==Overview==
[[Mitral regurgitation]] ([[MR]]) refers to a disorder of the heart in which the [[mitral valve]] fails to close properly during [[systole]] leading to leakage of blood from [[left ventricle]] to [[left atrium]] during [[systole]] and reduction in [[cardiac output]].  The symptoms associated with [[mitral regurgitation]] are depends on the phase of the disease process.  Individuals with [[acute mitral regurgitation]] are often gravely ill with significant hemodynamic abnormalities due to [[decompensated congestive heart failure]] and low [[cardiac output]] that require urgent treatment, whereas individuals with chronic compensated mitral regurgitation may be asymptomatic, with a normal exercise tolerance and no evidence of [[heart failure]].<ref name="pmid19564568">{{cite journal| author=Stout KK, Verrier ED| title=Acute valvular regurgitation. | journal=Circulation | year= 2009 | volume= 119 | issue= 25 | pages= 3232-41 | pmid=19564568 | doi=10.1161/CIRCULATIONAHA.108.782292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19564568  }} </ref>  The management of acute [[MR]] is mitral valve surgery in most cases, whereas the chronic [[MR]] management depends on whether the condition is chronic primary [[MR]] (the [[mitral valve]] is usually abnormal) or chronic secondary [[MR]] (the [[mitral valve]] is usually normal) and the severity of the valve anatomy.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>
[[Mitral regurgitation]] ([[MR]]) is a disorder of the heart characterized by failure of the [[mitral valve]] to close properly during [[systole]] leading to blood leakage from the [[left ventricle]] to the [[left atrium]] during [[systole]].  Individuals with [[acute mitral regurgitation]] may present with significant hemodynamic instability due to the sudden drop in [[cardiac output]], leading to acute pulmonary edema, hypotension and possible cardiogenic shock. Individuals with chronic compensated mitral regurgitation may be asymptomatic, with a normal exercise tolerance and no evidence of [[heart failure]], or may present with fatigue, dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea.<ref name="pmid19564568">{{cite journal| author=Stout KK, Verrier ED| title=Acute valvular regurgitation. | journal=Circulation | year= 2009 | volume= 119 | issue= 25 | pages= 3232-41 | pmid=19564568 | doi=10.1161/CIRCULATIONAHA.108.782292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19564568  }} </ref>  The management of [[MR]] includes afterload reduction with careful monitoring of fluid status, management of the underlying disease (CAD, mitral valve prolapse, rheumatic heart disease), and early surgical intervention in severe cases. Ultimately, the management of MR depends on the anatomy of the mitral valve, the acuteness of the disease process, and the severity of presentation. <ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>


==Causes==
==Causes==
Line 38: Line 38:
===Common Causes===
===Common Causes===
====Acute Mitral Regurgitation====
====Acute Mitral Regurgitation====
* [[Papillary muscle rupture]]: [[Acute myocardial infarction]], [[chest trauma]], [[ischemia]]
* [[Papillary muscle rupture]]:
* [[Myocardial rupture|Ruptured mitral chordae tendinae]]: [[Acute rheumatic fever]], [[chest trauma]], [[mitral valve prolapse]], [[infective endocarditis]], spontaneous rupture<ref name="pmid6837414">{{cite journal| author=Grenadier E, Alpan G, Keidar S, Palant A| title=The prevalence of ruptured chordae tendineae in the mitral valve prolapse syndrome. | journal=Am Heart J | year= 1983 | volume= 105 | issue= 4 | pages= 603-10 | pmid=6837414 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6837414 }} </ref><ref name="pmid9580528">{{cite journal| author=Grinberg AR, Finkielman JD, Piñeiro D, Festa H, Cazenave C| title=Rupture of mitral chorda tendinea following blunt chest trauma. | journal=Clin Cardiol | year= 1998 | volume= 21 | issue= 4 | pages= 300-1 | pmid=9580528 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9580528  }} </ref><ref name="pmid17854408">{{cite journal| author=Anderson Y, Wilson N, Nicholson R, Finucane K| title=Fulminant mitral regurgitation due to ruptured chordae tendinae in acute rheumatic fever. | journal=J Paediatr Child Health | year= 2008 | volume= 44 | issue= 3 | pages= 134-7 | pmid=17854408 | doi=10.1111/j.1440-1754.2007.01214.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17854408 }} </ref>  
** [[Acute myocardial infarction]]
** [[Chest trauma]]
* [[Myocardial rupture|Ruptured mitral chordae tendinae]]:
** [[Acute rheumatic fever]]<ref name="pmid17854408">{{cite journal| author=Anderson Y, Wilson N, Nicholson R, Finucane K| title=Fulminant mitral regurgitation due to ruptured chordae tendinae in acute rheumatic fever. | journal=J Paediatr Child Health | year= 2008 | volume= 44 | issue= 3 | pages= 134-7 | pmid=17854408 | doi=10.1111/j.1440-1754.2007.01214.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17854408 }} </ref>  
** [[Chest trauma]]<ref name="pmid9580528">{{cite journal| author=Grinberg AR, Finkielman JD, Piñeiro D, Festa H, Cazenave C| title=Rupture of mitral chorda tendinea following blunt chest trauma. | journal=Clin Cardiol | year= 1998 | volume= 21 | issue= 4 | pages= 300-1 | pmid=9580528 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9580528  }} </ref>
** [[Mitral valve prolapse]]<ref name="pmid6837414">{{cite journal| author=Grenadier E, Alpan G, Keidar S, Palant A| title=The prevalence of ruptured chordae tendineae in the mitral valve prolapse syndrome. | journal=Am Heart J | year= 1983 | volume= 105 | issue= 4 | pages= 603-10 | pmid=6837414 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6837414 }} </ref>
** [[Infective endocarditis]]
** Spontaneous rupture
 
====Chronic Primary Mitral Regurgitation====
====Chronic Primary Mitral Regurgitation====
* [[Marfan's syndrome]]
* [[Marfan's syndrome]]
Line 45: Line 53:
* [[Mitral valve prolapse]]  
* [[Mitral valve prolapse]]  
* [[Myxomatous degeneration]]
* [[Myxomatous degeneration]]
====Chronic Secondary Mitral Regurgitation====
====Chronic Secondary Mitral Regurgitation====
* [[Dilated cardiomyopathy]]
* [[Dilated cardiomyopathy]]
* [[Infective endocarditis]]
* [[Infective endocarditis]]
* [[Ischemic heart disease]]<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>
* [[Ischemic heart disease]]<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>


Click '''[[Mitral regurgitation causes|here]]''' for the complete list of causes.
Click '''[[Mitral regurgitation causes|here]]''' for the complete list of causes.
Line 56: Line 64:
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.


<span style="font-size:85%">Boxes in salmon color signify that an urgent management is needed.</span>
<span style="font-size:85%">Boxes in red color signify that an urgent management is needed.</span>
 
<span style="font-size:85%">'''Abbreviations:''' '''ARBs''': Angiotensin II receptor antagonist; '''CABG''': Coronary artery bypass surgery; '''HF''': Heart failure; '''IE''': Infective endocarditis; '''LVEF''': Left ventricular ejection fraction; '''LV''': Left ventricle; '''MR''': Mitral regurgitation;  '''S1''': First heart sound; '''S2''': Second heart sound </span> <br>
<span style="font-size:85%">'''ARBs''': Angiotensin II receptor antagonist; '''CABG''': Coronary artery bypass surgery; '''HF''': Heart failure; '''IE''': Infective endocarditis; '''LVEF''': Left ventricular ejection fraction; '''LV''': Left ventricle; '''MR''': Mitral regurgitation;  '''S1''': First heart sound; '''S2''': Second heart sound </span> <br>
{{Family tree/start}}
{{Family tree/start}}
{{familytree  | | | | | | | | | A01 | | | | | | | | | A01=<div style="width:25em">'''Identify cardinal findings that increase the pretest probability of mitral regurgitation:'''</div><br><div style="width:22em; text-align:left">
{{familytree  | | | | | | | | | A01 | | | | | | | | | A01=<div style="width:25em">'''Identify cardinal findings that increase the pretest probability of mitral regurgitation:'''</div><br><div style="width:22em; text-align:left">
❑ [[Murmur]]:
❑ [[Murmur]]:
:❑ High pitched and blowing [[holosystolic murmur]] (typical)
:❑ Soft, low pitched and decrescendo (in acute [[MR]] due to diminished pressure gradient between the [[left atrium]] and [[ventricle]])
:❑ Best heard over the [[apex]] radiating to the [[axilla]] and back
:❑ High pitched and blowing [[holosystolic murmur]] best heard over the [[apex]] radiating to the [[axilla]] and back
:❑ Other:
:❑ Silent (in acute [[ischemic MR]])
::❑ Soft, low pitched and decrescendo (in acute [[MR]] due to diminished pressure gradient between the [[left atrium]] and [[ventricle]])
::❑ Silent (in acute [[ischemic MR]])
❑ [[Heart sounds]]:
❑ [[Heart sounds]]:
:❑ [[S1]] is diminished (typical)
:❑ [[S1]] is diminished (typical)
Line 77: Line 82:
:❑ [[Tachypnea]]<br>
:❑ [[Tachypnea]]<br>
:❑ [[Crackles]] or [[rales]] <br>
:❑ [[Crackles]] or [[rales]] <br>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]] <BR>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]]: <BR>
:❑ [[Tachycardia]] <br>
:❑ [[Hypotension]]<br>
:❑ [[Altered mental status]]<br>
:❑ [[Altered mental status]]<br>
:❑ [[Oliguria]]<br>
:❑ [[Oliguria]]<br>
:❑ [[Cyanosis]]
:❑ [[Diaphoresis]]
:❑ [[Diaphoresis]]
:❑ [[Tachycardia]] <br>
:❑ [[Cold extremities]]
:❑ [[Hypotension]]<br>
:❑ [[Peripheral cyanosis]]
❑ History of heart disease: <br>
:❑ [[Mottling]]
:❑ [[Congestive heart failure]]<br>
</div>}}
:❑ [[Coronary heart disease]]<br>
:❑ [[Rheumatic heart disease]] and [[infective endocarditis]] <br> </div>}}
{{familytree  | | | | | | | |,|-|^|-|.| | | | |}}
{{familytree  | | | | | | | |,|-|^|-|.| | | | |}}
{{familytree  |boxstyle= padding: 0; background: #FA8072; text-align: center;| | | | | | A01 | | | A02 | | | | |A01={{fontcolor|#F8F8FF|'''Yes'''}}| A02=<div style="text-align: center; background: #FFFFFF; height: 25px; line-height: 25px;">'''No'''</div>}}
{{familytree  |boxstyle= padding: 0; background: #FA8072; text-align: center;| | | | | | A01 | | | A02 | | | | |A01={{fontcolor|#F8F8FF|'''Yes'''}}| A02=<div style="text-align: center; background: #FFFFFF; height: 25px; line-height: 25px;">'''No'''</div>}}
{{familytree  | | | | | | | |!| | | |!| | }}
{{familytree  | | | | | | | |!| | | |!| | }}
{{familytree  | | | | | | | |!| | | A02 | | | | | | A02= [[Mitral regurgitation resident survival guide#Complete Diagnostic Approach|'''Continue with complete diagnostic approach below''']]}}
{{familytree  | | | | | | | |!| | | A02 | | | | | | A02= [[Mitral regurgitation resident survival guide#Complete Diagnostic Approach|'''Continue with complete diagnostic approach below''']]}}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | |  A01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Initial resuscitative measures:'''<br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | |  A01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
----
❑ Secure airway <br>
❑ Secure airway <br>
❑ O2 <br>
Administer O2 <br>
❑ 2 wide bore IV access <br>
Establish 2 wide bore IV access <br>
Arterial line<br>
Establish an arterial line<br>
❑ ECG monitor<br>
Connect to ECG monitor<br>
❑ Monitor vitals continuously<br>
❑ Monitor vitals continuously<br>
❑ ICU admission
Consider ICU admission<br>
----
❑ Consider [[mechanical ventilation|<span style="color:white;">mechanical ventilation</span>]]<br>
'''Order [[transthoracic echocardiography|<span style="color:white;">transthoracic echocardiography</span>]] ([[TTE|<span style="color:white;">TTE</span>]]) (urgent):'''<br>
❑ Consider [[pulmonary artery catheterization|<span style="color:white;">pulmonary artery catheterization</span>]]
----
❑ Confirmatory<br>
❑ To determine severity and assess hemodynamic consequences <br>
❑ To establish etiology<br>
❑ To determine prognosis and evaluate for timing of intervention
----
'''Order other investigations (urgent):'''<br>
----
----
'''Order imaging and blood tests (urgent):'''<br>
❑ [[Transthoracic echocardiography|<span style="color:white;">Transthoracic echocardiography</span>]] ([[TTE|<span style="color:white;">TTE</span>]])<br>
❑ [[Chest X-ray|<span style="color:white;">Chest X-ray</span>]]<br>
❑ [[Chest X-ray|<span style="color:white;">Chest X-ray</span>]]<br>
❑ [[CBC|<span style="color:white;">CBC</span>]] <br>
❑ [[CBC|<span style="color:white;">CBC</span>]] <br>
❑ [[Serum electrolytes|<span style="color:white;">Serum electrolytes</span>]]<br>
❑ [[Serum electrolytes|<span style="color:white;">Serum electrolytes</span>]]<br>
❑ [[Blood cultures|<span style="color:white;">Blood cultures</span>]] (in case of fever)  <br>
❑ Serum cardiac [[troponin|<span style="color:white;">troponin</span>]] I and T  <br>
❑ Serum cardiac [[troponin|<span style="color:white;">troponin</span>]] I and T  <br>
❑ [[Creatine kinase|<span style="color:white;">Creatine kinase</span>]] (CK-MB)  <br>
❑ [[Creatine kinase|<span style="color:white;">Creatine kinase</span>]] (CK-MB)  <br>
❑ Serum [[urea|<span style="color:white;">urea</span>]] and [[creatinine|<span style="color:white;">creatinine</span>]]  <br>
❑ Serum [[urea|<span style="color:white;">urea</span>]] and [[creatinine|<span style="color:white;">creatinine</span>]]  <br>
</div>}}
{{familytree  | | | | | | | |!| | | | | | }}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | A01='''Does the patient has any evidence of MR in TTE?'''}}
{{familytree  | | | | | |,|-|^|-|.| | | | }}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | A02 | | | A01=Yes| A02=No}}
{{familytree  | | | | | |!| | | |!| | | | }}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | A02 | | | A01= <div style="text-align: left; width: 18em; padding: 1em;">
'''Stabilize the patient:'''<br>
❑ Initiate medical stabilization:
:❑ [[Vasodilator|<span style="color:white;">Vasodilator</span>]] (IV [[nitroprusside|<span style="color:white;">nitroprusside</span>]]) '''PLUS''' inotropic agents (IV [[dobutamine|<span style="color:white;">dobutamine</span>]]) <br>
❑ Establish [[intra-aortic balloon pump|<span style="color:white;">intra-aortic balloon pump</span>]]:<br>
:❑ If medical therapy is not effective to maintain hemodynamic stability<br>
----
----
'''Initiate medical therapy:'''<br>
'''Initiate treatment for specific etiologies:'''<br>
----
❑ [[Aspirin|<span style="color:white;">Aspirin</span>]] in case of myocardial infarction<br>
❑ [[Vasodilator|<span style="color:white;">Vasodilator</span>]] therapy: IV [[nitroprusside|<span style="color:white;">nitroprusside</span>]]<br>
❑ Antibiotics in case of [[Infective endocarditis resident survival guide|<span style="color:white;">infective endocarditis</span>]]  
'''AND'''<br>
</div>| A02= <div style="text-align: left; width: 18em; padding: 1em;">'''Consider other possible diagnosis:'''<br>
❑ Inotropic agents: IV [[dobutamine|<span style="color:white;">dobutamine</span>]]<br>
❑ [[Acute respiratory distress syndrome|<span style="color:white;">Acute respiratory distress syndrome</span>]]  
----
❑ [[Sepsis|<span style="color:white;">Sepsis</span>]]<br>
'''Consider the following:'''<br>
</div>}}
----
{{familytree  | | | | | |!| | | | | | }}  
❑ [[Mechanical ventilation|<span style="color:white;">Mechanical ventilation</span>]]<br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | A01 | | | | | | A01= <div style="text-align: left; width: 18em; padding: 1em;">'''Does the patient have any findings on TTE that require mitral valve surgery?'''<br>
❑ [[Pulmonary artery catheterization|<span style="color:white;">Pulmonary artery catheterization</span>]]</div>}}
Flail mitral leaflet (papillary muscle or chordal rupture)<br>
{{familytree  | | | | | | | |!| | | | | | }}  
Any signs of [[endocarditis|<span style="color:white;">endocarditis</span>]] <br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | | | | | A01 | | | | | | A01=Etiology established through clinical, imaging and laboratory findings}}
:❑ Vegetations on the leaflets
{{familytree  | | | |,|-|-|-|+|-|-|-|.| | | | | | | }}
:❑ Paravalvular abscess
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | Z01 | | Z02 | | Z03 | | | | | | Z01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> ''''''Ischemic mitral regurgitation:''''''<br>
Moderate to severe ischemic MR <br></div>}}
'''Initiate medical therapy:'''<br>
{{familytree  | | | |,|-|^|-|.| | | | }}
----
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | A02 | | | | A01=Yes| A02=No}}
In cases of reduced LVEF (ischemic cardiomyopathy)<br>
{{familytree  | | | |!| | | |!| | | | | }}
Medications: <br>
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | A02 | | | | A01=<div style="text-align: left; width: 18em; padding: 1em;">'''Perform mitral valve surgery:'''<br>
:❑ [[Angiotensin converting enzyme inhibitors|<span style="color:white;">Angiotensin converting enzyme inhibitors</span>]]
:❑ [[Angiotensin II receptor blockers|<span style="color:white;">Angiotensin II receptor blockers</span>]]<br>
:[[Beta blockers|<span style="color:white;">Beta blockers</span>]]
----
'''[[Intra-aortic balloon pump|<span style="color:white;">Intra-aortic balloon pump</span>]]:'''<br>
----
❑ To improve forward [[cardiac output|<span style="color:white;">cardiac output</span>]]<br>
❑ To reduce the impact on regurgitant volume
----
'''Reperfusion or revascularization:'''<br>
----
❑ [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] <br>
❑ Early reperfusion can reduce localized [[LV|<span style="color:white;">LV</span>]] remodeling and hence [[MR|<span style="color:white;">MR</span>]]<br>
----
'''Mitral valve surgery:'''<br>
----
❑ [[Papillary muscle rupture|<span style="color:white;">Papillary muscle rupture</span>]]<br>
❑ Moderate to severe [[ischemic MR|<span style="color:white;">ischemic MR</span>]] who are undergoing [[CABG|<span style="color:white;">CABG</span>]]<br>
❑ [[Mitral valve repair|<span style="color:white;">Mitral valve repair</span>]]: <br>
❑ [[Mitral valve repair|<span style="color:white;">Mitral valve repair</span>]]: <br>
:❑ Most preferred
:❑ Most preferred
:❑ Done in absence of [[papillary muscle|<span style="color:white;">papillary muscle</span>]] necrosis
:❑ Done in absence of [[papillary muscle|<span style="color:white;">papillary muscle</span>]] necrosis
❑ [[Mitral valve replacement|<span style="color:white;">Mitral valve replacement</span>]]:
❑ [[Mitral valve replacement|<span style="color:white;">Mitral valve replacement</span>]]:
:❑ In complex MR with extensive destruction
:❑ Performed in cases of complex MR with extensive tissue destruction
:❑ Lateral LV wall motion abnormality  
:❑ Performed in cases of MR with lateral LV wall motion abnormality  
</div>| A02=<div style="text-align: left; width: 18em; padding: 1em;">'''Perform reperfusion or revascularization:'''<br>
----
----
'''Cardiac transplantation:'''<br>
❑ In patients with acute coronary syndrome, [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] should be performed<br>
❑ Early reperfusion for [[myocardial infarction|<span style="color:white;">myocardial infarction</span>]] can reduce localized [[LV|<span style="color:white;">LV</span>]] remodeling and hence [[MR|<span style="color:white;">MR</span>]]
 
</div>}}
{{familytree  | | | |!| | | | | | | | }}
{{familytree  |boxstyle=background: #FA8072; color: #F8F8FF;| | A01 | | | | | | A01=<div style="text-align: left; width: 18em; padding: 1em;">'''Perform reperfusion or revascularization:'''<br>
❑ Perform [[CABG|<span style="color:white;">CABG</span>]] or [[coronary angioplasty|<span style="color:white;">coronary angioplasty</span>]] at the time of mitral valve surgery in patients with myocardial infarction<br>
----
----
'''Consider cardiac transplantation:'''<br>
❑ On some occasions with no contraindication for surgery<br>
❑ On some occasions with no contraindication for surgery<br>
In patients with severe LV dysfunction  
For patients with severe LV dysfunction  
</div>|Z02=<div style="float: left; text-align: left; width: em; padding:1em;">''''''MR due to acute exacerbation of HF:'''''' <br>
'''Heart failure management:''' <br>
----
❑ Click [[Acute heart failure resident survival guide|<span style="color:white;">'''here'''</span>]] for acute heart failure resident survival guide
:❑ [[ACE inhibitors|<span style="color:white;">ACE inhibitors</span>]] or ([[ARBs|<span style="color:white;">ARBs</span>]]) if LVEF is ≤ 40%
:❑ [[Beta blockers|<span style="color:white;">Beta blockers</span>]]
:❑ Intravenous inotropic drugs ([[dobutamine|<span style="color:white;">dobutamine</span>]])
:❑ [[Diuretic therapy|<span style="color:white;">Diuretic therapy</span>]]
:❑ IV [[vasodilators|<span style="color:white;">vasodilators</span>]]
----
'''Mitral valve surgery:'''<br>
----
❑ When there is no response to medical management
❑ [[Mitral valve replacement|<span style="color:white;">Mitral valve replacement</span>]] or [[mitral valve repair|<span style="color:white;">mitral valve repair</span>]] </div>| Z03=<div style="float: left; text-align: left; width: 16em; padding:1em;">''''''MR due to infective endocarditis:''''''<br>
----
'''Initiate medical therapy:'''<br>
----
❑ Click [[Endocarditis antimicrobial treatment|<span style="color:white;">'''here'''</span>]] for [[infective endocarditis|<span style="color:white;">'''infective endocarditis'''</span>]] resident survival guide and antimicrobial treatment<br>
----
'''Mitral valve surgery:'''<br>
----
❑ Urgent surgery:
:❑ Persistent [[heart failure|<span style="color:white;">heart failure</span>]]
:❑ [[Pulmonary hypertension|<span style="color:white;">Pulmonary hypertension</span>]]
:❑ Early mitral valve closure
❑ [[Mitral valve replacement|<span style="color:white;">Mitral valve replacement</span>]]:
:❑ Mostly done
:❑ Due to extensive tissue destruction
❑ [[Mitral valve repair|<span style="color:white;">Mitral valve repair</span>]]: <br>
:❑ If less [[mitral valve|<span style="color:white;">mitral valve</span>]] destruction
</div>}}
</div>}}
{{Family tree/end}}
{{Family tree/end}}


==Complete Diagnostic Approach to Mitral Regurgitation==
==Complete Diagnostic Approach to Mitral Regurgitation==
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.  Shown below is an algorithm summarizing the complete diagnostic approach to mitral regurgitation according to 2014 AHA/ACC guidelines for management of valvular heart disease.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
<span style="font-size:85%">'''AF''': Atrial fibrillation; '''MR''': Mitral regurgitation; '''EKG''': Electrocardiogram; '''EF''': Ejection fraction; '''S1''': First heart sound; '''S2''': Second heart sound; '''S3''': Third heart sound; '''LV''': Left ventricle; '''MVP''': Mitral valve prolapse</span> <br>
<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''MR''': Mitral regurgitation; '''EKG''': Electrocardiogram; '''EF''': Ejection fraction; '''S1''': First heart sound; '''S2''': Second heart sound; '''S3''': Third heart sound; '''LV''': Left ventricle; '''MVP''': Mitral valve prolapse</span> <br>


{{family tree/start}}
{{family tree/start}}
{{family tree| | | | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Characterize the symptoms:'''<br>
{{family tree| | | | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Characterize the symptoms:'''<br>
----
'''Acute mitral regurgitation:'''
'''Acute mitral regurgitation:'''
----
❑ '''Symptoms of [[shock]] and [[pulmonary edema]]:'''<br>
❑ '''Symptoms of [[shock]] and [[pulmonary edema]]:'''<br>
:❑ [[Shortness of breath]]<br>
:❑ [[Shortness of breath]]<br>
Line 225: Line 194:
----
----
'''Chronic mitral regurgitation:'''
'''Chronic mitral regurgitation:'''
----
❑ [[Asymptomatic]]  
❑ [[Asymptomatic]]  
:❑ Typical in isolated mild to moderate [[MR]]
:❑ Typical in isolated mild to moderate [[MR]]
:❑ Severe MR until there is [[left ventricular failure]], [[pulmonary hypertension]] or [[atrial fibrillation]]
:❑ Severe MR until there is [[left ventricular failure]], [[pulmonary hypertension]] or [[atrial fibrillation]]
❑ '''Symptoms associated with decreased forward flow and increased backflow across mitral valve:'''<br>
❑ '''Symptoms associated with decreased forward flow and increased backflow across mitral valve (left ventricular failure):'''<br>
:❑ [[Exertional dyspnea]]<br>
:❑ [[Exertional dyspnea]]<br>
:❑ [[Orthopnea]]<br>
:❑ [[Orthopnea]]<br>
Line 251: Line 219:
::❑ [[edema|Pedel edema]]
::❑ [[edema|Pedel edema]]
::❑ [[Abdominal pain]] ([[hepatomegaly]])
::❑ [[Abdominal pain]] ([[hepatomegaly]])
❑ '''Other etiology associated symptoms:'''<br>
:❑ [[Joint pains]] (suggestive of rheumatic etiology)<br>
:❑ Skin lesions (suggestive of rheumatic etiology)<br>
  </div>}}
  </div>}}
{{family tree| | | | | | | |!| | | | | | }}
{{family tree| | | | | | | |!| | | | | | }}
Line 327: Line 292:


'''Abdominal system:''' <br>
'''Abdominal system:''' <br>
[[Hepatojugular reflex]]<br>
❑ Hepatojugular reflex<br>
❑ [[Hepatomegaly]] <br>
❑ [[Hepatomegaly]] <br>
❑ [[Ascites]]<br>
❑ [[Ascites]]<br>
Line 336: Line 301:
{{Family tree| | | | | | | |!| | | | | | }}
{{Family tree| | | | | | | |!| | | | | | }}
{{Family tree| | | | | | | D01 | | | | | D01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Order [[electrocardiogram]] (urgent):'''  
{{Family tree| | | | | | | D01 | | | | | D01= <div style="float: left; text-align: left; width:25em; padding:1em;">'''Order [[electrocardiogram]] (urgent):'''  
----
❑ In [[MR|acute MR]]<br>
❑ In [[MR|acute MR]]<br>
:❑ Mostly normal
:❑ Mostly normal
Line 346: Line 310:
:❑ Findings of [[Atrial fibrillation electrocardiogram|atrial fibrillation]] complication
:❑ Findings of [[Atrial fibrillation electrocardiogram|atrial fibrillation]] complication
[[Image:P mitrale.gif|center|150px|thumb|Left atrial enlargement produces a broad, bifid P wave in lead II ('''P mitrale''')]]
[[Image:P mitrale.gif|center|150px|thumb|Left atrial enlargement produces a broad, bifid P wave in lead II ('''P mitrale''')]]
----
 
'''Order [[chest X-ray]] (urgent):'''<br>
'''Order [[chest X-ray]] (urgent):'''<br>
----
❑ [[MR|Acute MR]]<br>
❑ [[MR|Acute MR]]<br>
:❑ Normal size cardiac silhouette  
:❑ Normal size cardiac silhouette  
Line 358: Line 321:


[[Image:mitral-valve02.jpg|150px|center|thumb|Calcification of the mitral annulus around the margins of the posterior leaflet forming a “C”]]<br clear="left"/>
[[Image:mitral-valve02.jpg|150px|center|thumb|Calcification of the mitral annulus around the margins of the posterior leaflet forming a “C”]]<br clear="left"/>
----
 
'''Order [[transthoracic echocardiography]] ([[TTE]]) (urgent):'''<br>
'''Order [[transthoracic echocardiography]] ([[TTE]]) (urgent):'''<br>
----
❑ Confirmatory<br>
❑ Confirmatory<br>
❑ To determine severity and assess hemodynamic consequences <br>
❑ To determine severity and assess hemodynamic consequences <br>
❑ To establish etiology<br>
❑ To establish etiology<br>
❑ To determine prognosis and evaluate for timing of intervention
❑ To determine prognosis and evaluate for timing of intervention
----
 
'''Order lab tests:'''<br>
'''Order lab tests:'''<br>
----
❑ [[CBC]]<br>
❑ [[CBC]]<br>
❑ [[Electrolytes]] <br>
❑ [[Electrolytes]] <br>
Line 373: Line 334:
❑ [[Troponin|Serum cardiac troponin I and T]]  <br>
❑ [[Troponin|Serum cardiac troponin I and T]]  <br>
❑ [[Creatine kinase]] (CK-MB)  <br>
❑ [[Creatine kinase]] (CK-MB)  <br>
❑ [[Blood cultures]] (in case of fever)  <br>
❑ Serum [[urea]] and [[creatinine]]  <br>
❑ Serum [[urea]] and [[creatinine]]  <br>
----
 
'''Other tests'''<br>
'''Other tests:'''<br>
----
❑ [[Transesophageal echocardiography]] ([[TEE]] if [[TTE]] is equivocal)<br>
❑ [[Transesophageal echocardiography]] ([[TEE]] if [[TTE]] is equivocal)<br>
❑ [[Cardiac catheterization]]:<br>
❑ [[Cardiac catheterization]]:<br>
Line 388: Line 349:
❑ [[MRI|Cardiac MRI]]<br>
❑ [[MRI|Cardiac MRI]]<br>
:❑ To assess severity when there is a discrepancy between clinical findings and [[echocardiography]]</div>}}
:❑ To assess severity when there is a discrepancy between clinical findings and [[echocardiography]]</div>}}
{{familytree | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | A01='''Does the patient has acute or chronic [[MR]]?'''}}
{{Family tree| | | |,|-|-|-|^|-|-|-|.| | }}
{{Family tree| | | |,|-|-|-|^|-|-|-|.| | }}
{{Family tree| | | F01 | | | | | | F02 | | | F01=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Cardinal findings that are suggestive of [[MR|acute mitral regurgitation]]'''<br>
{{Family tree| | | F01 | | | | | | F02 | | | F01=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Acute MR (Cardinal findings suggestive of [[MR|acute mitral regurgitation]])'''<br>
❑ Sudden onset and rapid progression of [[pulmonary edema]]<br>
❑ Sudden onset and rapid progression of [[pulmonary edema]]<br>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]] <BR>
❑ [[Cardiogenic shock physical examination|Signs and symptoms of cardiogenic shock]] <BR>
Line 400: Line 363:
:❑ Reduced EF
:❑ Reduced EF
:❑ Ruptured mitral [[chordae tendinae]] (flail leaflet)
:❑ Ruptured mitral [[chordae tendinae]] (flail leaflet)
:❑ Ruptured [[papillary muscle]]</div>| F02=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Cardinal findings that are suggestive of [[MR|chronic mitral regurgitation]]'''<br>
:❑ Ruptured [[papillary muscle]]</div>| F02=<div style="float: left; text-align: left; width:25em; padding:1em;">'''Chronic MR (cardinal findings suggestive of [[MR|chronic mitral regurgitation]])'''<br>
❑ Asymptomatic to chronic symptoms<br>
❑ Asymptomatic to chronic symptoms<br>
❑ Pre-existing [[heart disease]]<br>
❑ Pre-existing [[heart disease]]<br>
Line 411: Line 374:
:❑ Preserved to decreased [[EF]]</div>}}
:❑ Preserved to decreased [[EF]]</div>}}
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | F02 | | | | | | | | | | | | | | | | | | | | | F02=[[Mitral valve]] anatomy}}
{{familytree | | | | | | | | | | | F02 | | | | | | | | | | | | | | | | | | | | | F02='''Does the [[mitral valve]] anatomy appear normal in [[TTE]]?'''}}
{{Family tree| | | | | | | | | |,|-|^|-|.| |}}
{{Family tree| | | | | | | | | |,|-|^|-|.| |}}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G01=Normal| G02=Abnormal}}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G01=Yes| G02=No}}
{{familytree | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G01=Chronic primary [[mitral regurgitation]]| G02=Chronic secondary [[mitral regurgitation]]}}
{{familytree | | | | | | | | | G01 | | G02 | | | | | | | | | | | | | | | | | | | G02=Chronic primary [[mitral regurgitation]]| G01=Chronic secondary [[mitral regurgitation]]}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}
Line 422: Line 385:
===Treatment of Acute Mitral Regurgitation===
===Treatment of Acute Mitral Regurgitation===
Shown below is an algorithm summarizing the approach to the management of acute mitral regurgitation.<ref name="pmid19564568">{{cite journal| author=Stout KK, Verrier ED| title=Acute valvular regurgitation. | journal=Circulation | year= 2009 | volume= 119 | issue= 25 | pages= 3232-41 | pmid=19564568 | doi=10.1161/CIRCULATIONAHA.108.782292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19564568  }} </ref><ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
Shown below is an algorithm summarizing the approach to the management of acute mitral regurgitation.<ref name="pmid19564568">{{cite journal| author=Stout KK, Verrier ED| title=Acute valvular regurgitation. | journal=Circulation | year= 2009 | volume= 119 | issue= 25 | pages= 3232-41 | pmid=19564568 | doi=10.1161/CIRCULATIONAHA.108.782292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19564568  }} </ref><ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
<span style="font-size:85%"> '''IE''': Infective endocarditis; '''LV''': Left ventricle; '''LVEF''': Left ventricular ejection fraction; '''MR''': Mitral regurgitation; </span> <br>
<span style="font-size:85%">'''Abbreviations:'''  '''IE''': Infective endocarditis; '''LV''': Left ventricle; '''LVEF''': Left ventricular ejection fraction; '''MR''': Mitral regurgitation </span> <br>


{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | |A01=[[MR|Acute mitral regurgitation]]}}
{{familytree | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | |B01=<div style="float: left; text-align: left; padding:1em;">'''Does the patient has any signs of hemodynamic instability?''' <br>
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | }}
❑ [[Hypotension]]<br>
{{familytree | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | |B01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Assess if the patient is hemodynamically stable?''' <br>
❑ [[Cold extremities]]<br>
❑ Hemodynamic instability
❑ [[Cyanosis|Peripheral cyanosis]]<br>
:❑ [[Hypotension]]
❑ [[Altered mental status]]<br>
:❑ [[Cold extremities]]
:❑ [[Cyanosis|Peripheral cyanosis]]
:❑ [[Altered mental status]]
</div>}}
</div>}}
{{familytree | | | | | |,|-|-|^|-|-|.| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | |,|-|-|^|-|-|.| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | C01 | | | | C02 | | | | | | | | | | | | | | | | | | | | |C01='''Yes'''<br>(unstable)|C02='''No'''<br>(stable)}}
{{familytree | | | | | | | | | | C01 | | | | C02 | | | | | | | | | | | | | | | | | | | | |C01='''Yes'''|C02='''No'''}}
{{familytree | | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | D01 | | | | D02 | | | | | | | | | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initial resuscitative measures:'''<br>
{{familytree | | | | | | | | | | D01 | | | | D02 | | | | | | | | | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; width:18em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
----
❑ Secure airway <br>
❑ Secure airway <br>
❑ O2 <br>
Administer O2 <br>
❑ 2 wide bore IV access <br>
Establish 2 wide bore IV access <br>
Arterial line<br>
Establish an arterial line<br>
❑ ECG monitor<br>
Connect to [[ECG]] monitor<br>
❑ Monitor vitals continuously<br>
❑ Monitor vitals continuously<br>
❑ ICU admission
Consider [[ICU]] admission<br>
❑ Consider [[mechanical ventilation]]<br>
❑ Consider [[pulmonary artery catheterization]]
----
----
'''Initiate medical therapy:'''<br>
'''Stabilize the patient:'''<br>
----
❑ Initiate medical stabilization:
❑ [[Vasodilator]] therapy: IV [[nitroprusside]]<br>
:❑ [[Vasodilator]] (IV [[nitroprusside]]) '''PLUS''' inotropic agents (IV [[dobutamine]]) <br>
'''AND'''<br>
❑ Establish [[intra-aortic balloon pump]]:<br>
❑ Inotropic agents: IV [[dobutamine]]<br>
:If medical therapy is not effective to maintain hemodynamic stability<br>
----
</div>| D02=<div style="float: left; text-align: left; width:18em; padding:1em;"> '''Initiate resuscitative measures:'''<br>
'''Consider the following:'''<br>
Administer O2 <br>
----
Establish 2 wide bore IV access <br>
[[Mechanical ventilation]]<br>
❑ Connect to ECG monitor<br>
❑ [[Pulmonary artery catheterization]]</div>| D02=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initial resuscitative measures:'''<br>
----
❑ O2 <br>
❑ 2 wide bore IV access <br>
❑ Monitor vitals continuously<br>
❑ Monitor vitals continuously<br>
----
----
'''Initiate medical therapy:'''<br>
'''Initiate medical therapy:'''<br>
----
❑ [[Vasodilator]] therapy: IV  [[nitroprusside]]<br></div>}}
❑ [[Vasodilator]] therapy: IV  [[nitroprusside]]<br></div>}}
{{familytree | | | | | |`|-|-|v|-|-|'| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | |`|-|-|v|-|-|'| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |,|-|-|^|-|-|.| | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |,|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|.| | | | | | | | | | | | | }}
{{familytree | | | | | I01 | | | | I03 | | | | | | | | | | | | | | | | | | | I01=[[Ischemic mitral regurgitation]]| I03= Non-ischemic [[mitral regurgitation]]}}
{{familytree | | | | | I01 | | | | | | I02 | | | | | | I03 | | | | | | | | | | | I02=[[Ischemic mitral regurgitation]]| I03= [[MR]] due to heart failure  exacerbation(functional [[MR]])|I01= [[MR]] due to [[IE]] (organic [[MR]])}}
{{familytree | | | | | |!| | | |,|-|^|-|.| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |!| | | | | | | |!| | | | | | | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | |!| | | I02 | | I03 | | | | | | | | | | | | | | | | | | | | I02=[[MR]] due to heart failure  exacerbation(functional [[MR]])| I03= [[MR]] due to [[IE]] (organic [[MR]])}}
{{familytree | | | | | E01 | | | | | | E02 | | | | | | E03 | | | | | | | | | | | | | | | | |E02=<div style="float: left; text-align: left; width:12em; padding:1em;"> '''Perform reperfusion or revascularization surgery:'''<br>
{{familytree | | | | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | }}
❑ [[CABG]] or [[coronary angioplasty]] should be done to treat [[acute coronary syndrome]]  <br>
{{familytree | | | | | E01 | | E02 | | E03 | | | | | | | | | | | | | | | | |E01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Initiate medical therapy:'''<br>
❑ Early reperfusion can reduce localized [[LV]] remodeling and hence [[MR]]<br>
</div>| E03=<div style="float: left; text-align: left; width:12em; padding:1em;">'''Initiate treatment for heart failure:''' <br>
❑ Click [[Acute heart failure resident survival guide|here]] for acute heart failure resident survival guide
:❑ [[ACE inhibitors]] or ([[ARBs]]) if LVEF is ≤ 40%
:❑ [[Beta blockers]]
:❑ Intravenous inotropic drugs ([[dobutamine]])
:❑ [[Diuretic ]]therapy
:❑ IV [[vasodilators]]
</div>| E01=<div style="float: left; text-align: left; width:12em; padding:1em;">
'''Initiate IE medical therapy:'''<br>
----
----
❑ Click [[infective endocarditis resident survival guide|'''here''']] for [[infective endocarditis]] resident survival guide and antimicrobial treatment<br>
</div>}}
{{familytree | | | | | |!| | | | | | | |!| | | | | | | |!| | | | | | | | | | | | | | | }}
{{familytree | | | | | A01 | | | | | | A02 | | | | | | A03 | | | | | | | | | | | | | | A02='''Does the patient has any indications for mitral valve surgery?'''<br>
❑ [[Papillary muscle rupture]]<br>
❑ [[Chordae tendinae rupture]]<br>
❑ Moderate to severe [[ischemic MR]] who are undergoing [[CABG]]<br>| A03='''Does the patient show any hemodynamic improvement to medical therapy?''' | A01='''Does the patient has any indications for mitral valve surgery?'''<br>
❑ Hemodynamic instability<br>
❑ Persistent [[heart failure]]<br>
❑ [[Pulmonary hypertension]]<br>
❑ Early [[mitral valve]] closure<br> }}
{{familytree | | | |,|-|^|-|.| | | |,|-|^|-|.| | | |,|-|^|-|.| | | | | | | | | | | | | | }}
{{familytree | | | A01 | | A02 | | A03 | | A04 | | A05 | | A06 | | | | | | | | | | | | A01=Yes|A02=No|A03=Yes|A04=No|A05=Yes|A06=No}}
{{familytree | | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | }}
{{familytree | | | A01 | | A02 | | A03 | | A04 | | A05 | | A06 | | | | | | | | | | | | A03=<div style="float: left; text-align: left; padding:1em;"> '''Perform mitral valve surgery:'''<br>
❑ Done at the time of reperfusion<br>
❑ [[Mitral valve repair]]: <br>
:❑ Most preferred
❑ [[Mitral valve replacement]]: Preferred in the following groups
:❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
:❑ Very ill patients presenting after an acute [[MI]]
:❑ Complex MR
:❑ In cases of lateral [[LV]] wall motion abnormality
</div>| A04=<div style="float: left; text-align: left; padding:1em;">
'''Consider medical therapy:'''<br>
❑ In cases of reduced LVEF (ischemic cardiomyopathy)<br>
❑ In cases of reduced LVEF (ischemic cardiomyopathy)<br>
❑ Medications: <br>
❑ Medications: <br>
:❑ [[Angiotensin converting enzyme inhibitors]]
:❑ [[Angiotensin converting enzyme inhibitors]]
:❑ [[Angiotensin II receptor blockers]]<br>
:❑ [[Angiotensin II receptor blockers]]<br>
:❑ [[Beta blockers]]
:❑ [[Beta blockers]]  
----
----  
'''[[Intra-aortic balloon pump]]:'''<br>
 
----
'''Consider cardiac transplantation:'''<br>
To improve forward [[cardiac output]]<br>
On some occasions in patients with severe [[LV]] dysfunction  with no contraindication for surgery<br>
❑ To reduce the impact on regurgitant volume
</div>| A05= Continue with the [[heart failure]] management and have appropriate follow ups to assess the severity of [[MR]]| A06=<div style="float: left; text-align: left; padding:1em;"> '''Consider mitral valve surgery:'''<br>
----
'''Reperfusion or revascularization:'''<br>
----
❑ [[CABG]] or [[coronary angioplasty]] <br>
❑ Early reperfusion can reduce localized [[LV]] remodeling and hence [[MR]]<br>
----
'''Mitral valve surgery:'''<br>
----
❑ [[Papillary muscle rupture]]<br>
❑ Moderate to severe [[ischemic MR]] who are undergoing [[CABG]]<br>
❑ [[Mitral valve repair]]: <br>
❑ [[Mitral valve repair]]: <br>
:❑ Most preferred
:❑ Most preferred
:❑ Done in absence of [[papillary muscle]] necrosis
❑ [[Mitral valve replacement]]:
❑ [[Mitral valve replacement]]:
:❑ In complex [[MR]] with extensive destruction
:❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
:❑ Lateral [[LV]] wall motion abnormality
:❑ In cases of lateral [[LV]] wall motion abnormality
</div>|A01=<div style="float: left; text-align: left; width: 16em; padding:1em;"> '''Perform mitral valve surgery:'''<br>
❑ [[Mitral valve replacement]]:
:❑ Mostly done
:❑ Due to extensive tissue destruction in [[IE]] patients
❑ [[Mitral valve repair]]: <br>
:❑ If less [[mitral valve]] destruction
</div>|A02=<div style="float: left; text-align: left; padding:1em;">
❑ Continue with medical management<br> </div>}}
{{familytree | | | |`|-|v|-|'| | | |!| | | | | | | | | | | |!| | | | | | | | | | | | | }}
{{familytree | | | | | A01 | | | | A04 | | | | | | | | | | A06 | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
----
----
'''Cardiac transplantation:'''<br>
For patients undergoing [[mitral valve replacement]]<br>
----
❑ [[Warfarin]]: Target INR 3 <br>
On some occasions with no contraindication for surgery<br>
❑ [[Aspirin]]: 75 to 100 mg/day
❑ In patients with severe [[LV]] dysfunction
</div>| E02=<div style="float: left; text-align: left; width: em; padding:1em;">'''Heart failure management:''' <br>
----
Click [[Acute heart failure resident survival guide|here]] for acute heart failure resident survival guide
:❑ [[ACE inhibitors]] or ([[ARBs]]) if LVEF is ≤ 40%
:❑ [[Beta blockers]]
:❑ Intravenous inotropic drugs ([[dobutamine]])
:❑ [[Diuretic ]]therapy
:❑ IV [[vasodilators]]
----
----
'''Mitral valve surgery:'''<br>
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
❑ For all patients <br>
❑ Indicated for the following procedures:
:❑ [[Endocarditis antibiotic prophylaxis#Basis for AHA Recommendations Regarding Antibiotic Prophylaxis for Dental Procedures|Dental procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis For Respiratory Tract Procedures|Respiratory tract procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis for Gastrointestinal (GI) and Genitourinary (GU) Procedures|GI and GU procedures]]
</div>|A04=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
----
----
When there is no response to medical management
For patients undergoing [[mitral valve replacement]]<br>
[[Mitral valve replacement]] or [[mitral valve repair]] </div>| E03=<div style="float: left; text-align: left; width: 16em; padding:1em;">
[[Warfarin]]: Target INR 3 <br>
'''Initiate medical therapy:'''<br>
❑ [[Aspirin]]: 75 to 100 mg/day
----
----
❑ Click [[infective endocarditis resident survival guide|'''here''']] for [[infective endocarditis]] resident survival guide and antimicrobial treatment<br>
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
❑ For patients who undergo [[mitral valve replacement]]<br>
❑ Indicated for the following procedures:
:❑ [[Endocarditis antibiotic prophylaxis#Basis for AHA Recommendations Regarding Antibiotic Prophylaxis for Dental Procedures|Dental procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis For Respiratory Tract Procedures|Respiratory tract procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis for Gastrointestinal (GI) and Genitourinary (GU) Procedures|GI and GU procedures]]
</div>|A06=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
----
----
'''Mitral valve surgery:'''<br>
❑ For patients undergoing [[mitral valve replacement]]<br>
❑ [[Warfarin]]: Target INR 3 <br>
❑ [[Aspirin]]: 75 to 100 mg/day
----
----
❑ Urgent surgery:
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
:❑ Persistent [[heart failure]]
For patients who undergo [[mitral valve replacement]]<br>
:❑ [[Pulmonary hypertension]]
❑ Indicated for the following procedures:
:Early [[mitral valve]] closure
:❑ [[Endocarditis antibiotic prophylaxis#Basis for AHA Recommendations Regarding Antibiotic Prophylaxis for Dental Procedures|Dental procedures]]  
❑ [[Mitral valve replacement]]:
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis For Respiratory Tract Procedures|Respiratory tract procedures]]
:❑ Mostly done
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis for Gastrointestinal (GI) and Genitourinary (GU) Procedures|GI and GU procedures]]
:❑ Due to extensive tissue destruction
❑ [[Mitral valve repair]]: <br>
:❑ If less [[mitral valve]] destruction
</div>}}
</div>}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}


Line 540: Line 529:
====Chronic Primary Mitral Regurgitation====
====Chronic Primary Mitral Regurgitation====
Shown below is an algorithm summarizing the approach to the management of chronic primary mitral regurgitation.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
Shown below is an algorithm summarizing the approach to the management of chronic primary mitral regurgitation.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
<span style="font-size:85%">'''AF''': Atrial fibrillation; '''IE''': Infective endocarditis; '''LVEF''': Left ventricular ejection fraction; '''LVESD''': Left ventricular end systolic dimension; '''MR''': Mitral regurgitation; '''MVP''': Mitral valve proplapse; '''PASP''': Pulmonary artery systolic pressure; '''RHD''': Rheumatic heart disease  </span> <br>
<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''IE''': Infective endocarditis; '''LVEF''': Left ventricular ejection fraction; '''LVESD''': Left ventricular end systolic dimension; '''MR''': Mitral regurgitation; '''MVP''': Mitral valve proplapse; '''PASP''': Pulmonary artery systolic pressure; '''RHD''': Rheumatic heart disease  </span> <br>
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | |A01=Chronic primary [[mitral regurgitation]]}}
{{familytree | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | A01=Determine the severity of [[MR]] on [[TTE]]}}
{{familytree | | | | |,|-|-|^|-|-|.| | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | |,|-|-|-|-|^|-|-|-|-|.| | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | C01 | | | | C02 | | | | | | | | | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Severe [[MR]]''': <br>
{{familytree | | | | C01 | | | | | | | | C02 | | | | | | | | | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Severe [[MR]]''': <br>
❑ Etiologies:
❑ Severe [[MVP]] with loss of coaptation<br>
:❑ Severe [[MVP]] with loss of coaptation
❑ [[Rheumatic fever|RHD]] with loss of central coaptation<br>
:❑ [[Rheumatic fever|RHD]] with loss of central coaptation
:❑ Prior [[IE]]
:❑ Radiation induced leaflet thickening
❑ [[Left ventricular dilation]]<br>
❑ [[Left ventricular dilation]]<br>
❑ Regurgitation fraction ≥ 50%<br>
❑ Regurgitation fraction ≥ 50%<br>
Line 555: Line 541:
❑ Effective regurgitation orifice ≥ 0.4cm²<br>
❑ Effective regurgitation orifice ≥ 0.4cm²<br>
❑ Vena contracta ≥ 0.7cm
❑ Vena contracta ≥ 0.7cm
</div>| C02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Progressive [[MR]]''' (Stage B): <br>
</div>| C02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Progressive [[MR]]''' ('''Stage B'''): <br>
❑ Etiologies:
❑ Severe [[MVP]] with normal coaptation<br>
:❑ Severe [[MVP]] with normal coaptation
❑ [[Rheumatic fever|RHD]] with normal coaptation<br>
:❑ [[Rheumatic fever|RHD]] with loss of central coaptation
:❑ Prior [[IE]]
❑ No [[Left ventricular dilation]]<br>
❑ No [[Left ventricular dilation]]<br>
❑ Regurgitation fraction < 50%<br>
❑ Regurgitation fraction < 50%<br>
Line 566: Line 550:
❑ Vena contracta < 0.7cm
❑ Vena contracta < 0.7cm
</div>}}
</div>}}
{{familytree | | |,|-|^|-|.| | | |!| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | |,|-|^|-|-|-|.| | | | | |!| | | | | | | | | | | | | | | | | | | | }}
{{familytree | | C01 | | C02 | | |!| | | | | | | | | | | | | | | | | | | | | | | C01=Symptomatic (Stage D)| C02=Asymptomatic (Stage C)}}
{{familytree | | C01 | | | | C02 | | | | |!| | | | | | | | | | | | | | | | | | | | | | | C01=Symptomatic ('''Stage D''')| C02=Asymptomatic ('''Stage C''')}}
{{familytree | | |!| | | |!| | | |!| | }}
{{familytree | | |!| | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | C01 | | C02 | | C03 | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate medical therapy:'''<br>
{{familytree | | |!| | | | | C02 | | | | |!| | | | | | | | | | | | | | | | | | | | | C02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Does the patient has any indications for mitral valve surgery?'''<br>
----
❑ [[LVEF]] 30 to ≤60% '''OR''' [[LVESD]] ≥ 40mm (Stage C2)<br>
❑ [[LVEF]] >60% '''AND''' LVESD < 40mm (Stage C1)<br>
:❑ With likelihood of successful repair > 95%
:❑ With expected mortality < 1%
❑ New onset [[AF]] '''OR''' PASP > 50mmHg (Stage C1)
:❑ With likelihood of successful repair > 95%
:❑ With expected mortality < 1% </div>}}
{{familytree | | |!| | | |,|-|^|-|.| | | |!| }}
{{familytree | | |!| | | C01 | | C02 | | |!| | | | | | | | | | | | | | | | | | | | | C01=Yes|C02=No}}
{{familytree | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | C01 | | C02 | | C03 | | C04 | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate medical therapy:'''<br>
❑ [[Vasodialators]]:<br>
❑ [[Vasodialators]]:<br>
:❑ Intravenous [[nitroprusside]]
:❑ Intravenous [[nitroprusside]]
Line 578: Line 572:
❑ [[Calcium channel blocker]]<br>
❑ [[Calcium channel blocker]]<br>
----
----
'''Mitral valve surgery:'''<br>
'''Perform mitral valve surgery:'''<br>
----
❑ [[Mitral valve repair]]: <br>
❑ [[Mitral valve repair]]: <br>
:❑ Mostly preferred
:❑ Mostly preferred
❑ [[Mitral valve replacement]]:
❑ [[Mitral valve replacement]]:
:❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
----
----
'''Revascularisation:'''<br>
'''Perform revascularisation:'''<br>
----
In cases with concurrent [[coronary artery disease]]<br>
Concurrent [[coronary artery disease]]<br>
❑ Revascularized at the time of [[mitral valve surgery]]<br>
❑ Revascularized at the time of [[mitral valve surgery]]<br>
----
 
'''Anticoagulation therapy:'''<br>
</div>|C02=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Perform mitral valve surgery:'''<br>
----
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Rheumatic [[mitral valve disease]] who have a history of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ Recurrent [[embolism]] despite adequate [[anticoagulation]]
----
'''Endocarditis prophylaxis:'''<br>
----
❑ [[Endocarditis antimicrobial treatment|Initiate infective endocarditis antimicrobial prophylaxis after mitral valve surgery]]<br>
</div>|C02=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Mitral valve surgery:'''<br>
----
❑ Performed in the following patients:
:❑ [[LVEF]] 30 to ≤60% '''OR''' [[LVESD]] ≥ 40mm (Stage C2)
:❑ [[LVEF]] >60% '''AND''' LVESD < 40mm (Stage C1)
::❑ With likelihood of successful repair > 95%
::❑ With expected mortality < 1%
:❑ New onset [[AF]] '''OR''' PASP > 50mmHg (Stage C1)
::❑ With likelihood of successful repair > 95%
::❑ With expected mortality < 1%
❑ [[Mitral valve repair]]: <br>
❑ [[Mitral valve repair]]: <br>
:❑ Mostly preferred
:❑ Mostly preferred
❑ [[Mitral valve replacement]]:
❑ [[Mitral valve replacement]]:
:❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
----
----
'''Revascularization:'''<br>
'''Perform revascularization:'''<br>
----
For patients with concurrent [[coronary artery disease]]<br>
Concurrent [[coronary artery disease]]<br>
❑ Revascularized at the time of [[mitral valve surgery]]<br>
❑ Revascularized at the time of [[mitral valve surgery]]<br>
----
</div>| C03=<div style="float: left; text-align: left; width: 20em; padding:1em;">
'''Periodic monitoring:'''<br>
'''Periodic monitoring:'''<br>
----
❑ In stage C1 patients with the following:
❑ In stage C1 patients with the following:
:❑ With likelihood of successful repair < 95%
:❑ With likelihood of successful repair < 95%
Line 635: Line 604:
❑ [[Echocardiography]]: <br>
❑ [[Echocardiography]]: <br>
:❑ Every 6 months
:❑ Every 6 months
</div>| C04=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Periodic monitoring:'''<br>
----
----
'''Anticoagulation therapy:'''<br>
❑ Clinical evaluation:
----
:❑ Every 3-6 months
❑ [[Echocardiography]]: <br>
:❑ Every 6 months
</div>}}
{{familytree | | |!| | | |`|-|v|-|'| | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | A01 | | | | B01 | | | | C01 | | | | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
❑ Indications:
:❑ Rheumatic [[mitral valve disease]] who have a history of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]
:❑ [[Mitral valve replacement]]
❑ [[Warfarin]]:
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Target INR 3 (for [[prosthetic valve]])
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ For patients with recurrent [[embolism]] despite adequate [[anticoagulation]]
:❑ For patients with [[prosthetic valve]]
----
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
❑ For patients who undergo [[mitral valve replacement]]<br>
❑ Indicated for the following procedures:
:❑ [[Endocarditis antibiotic prophylaxis#Basis for AHA Recommendations Regarding Antibiotic Prophylaxis for Dental Procedures|Dental procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis For Respiratory Tract Procedures|Respiratory tract procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis for Gastrointestinal (GI) and Genitourinary (GU) Procedures|GI and GU procedures]]
</div>|B01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
❑ Indications:
:❑ Rheumatic [[mitral valve disease]] who have a history of systemic [[embolism]]
:❑ Rheumatic [[mitral valve disease]] who have a history of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]  
:❑ Paroxysmal or chronic [[atrial fibrillation]]
:❑ [[Mitral valve replacement]]
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Target INR 3 (for [[prosthetic valve]])
❑ [[Aspirin]]: <br>
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ 75 to 100 mg/day
:❑ Recurrent embolism despite adequate anticoagulation
:❑ For patients with recurrent [[embolism]] despite adequate [[anticoagulation]]
----
:❑ For patients with [[prosthetic valve]]
'''Endocarditis prophylaxis:'''<br>
----
[[Endocarditis antimicrobial treatment|Initiate infective endocarditis antimicrobial prophylaxis for patients undergoing mitral valve surgery]]<br>
</div>| C03=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Periodic monitoring:'''<br>
----
❑ Clinical evaluation:
:❑ Every 3-6 months
[[Echocardiography]]: <br>
:❑ Every 6 months
----
'''Anticoagulation therapy:'''<br>
----
----
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
❑ For patients who undergo [[mitral valve replacement]]<br>
❑ Indicated for the following procedures:
:❑ [[Endocarditis antibiotic prophylaxis#Basis for AHA Recommendations Regarding Antibiotic Prophylaxis for Dental Procedures|Dental procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis For Respiratory Tract Procedures|Respiratory tract procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis for Gastrointestinal (GI) and Genitourinary (GU) Procedures|GI and GU procedures]]
</div>| C01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
❑ Indications:
:❑ Rheumatic [[mitral valve disease]] who have a history of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]
:❑ [[Mitral valve replacement]]
❑ [[Warfarin]]:
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Rheumatic [[mitral valve disease]] who have a history of systemic [[embolism]]
:❑ Target INR 3 (for [[prosthetic valve]])
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]  
❑ [[Aspirin]]: <br>
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ 75 to 100 mg/day
:❑ Recurrent embolism despite adequate anticoagulation
:❑ For patients with recurrent [[embolism]] despite adequate [[anticoagulation]]
</div>}}
:❑ For patients with [[prosthetic valve]]</div>}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}
Line 674: Line 673:
Shown below is an algorithm summarizing the approach to the management of chronic secondary mitral regurgitation.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>
Shown below is an algorithm summarizing the approach to the management of chronic secondary mitral regurgitation.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume=  | issue=  | pages=  | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852  }} </ref>.<br>


<span style="font-size:85%">'''AF''': Atrial fibrillation; '''CAD''': Coronary artery disease; '''HF''': Heart failure; '''IE''': Infective endocarditis; '''LV''': Left ventricle; '''MR''': Mitral regurgitation  </span> <br>
<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''CAD''': Coronary artery disease; '''HF''': Heart failure; '''IE''': Infective endocarditis; '''LV''': Left ventricle; '''MR''': Mitral regurgitation  </span> <br>
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | }}
{{familytree | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | |A01=Chronic secondary [[mitral regurgitation]]}}
{{familytree | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | |A01= Determine the etiology and initiate specific treatment}}
{{familytree | | | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Heart failure treatment''': <br>
{{familytree | | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Heart failure:''' <br>
❑ Click [[Acute heart failure resident survival guide|here]] for heart failure resident survival guide
❑ Click [[Acute heart failure resident survival guide|here]] for heart failure resident survival guide
:❑ [[ACE inhibitors]]  
:❑ [[ACE inhibitors]]  
Line 685: Line 684:
:❑ [[Beta blockers]]
:❑ [[Beta blockers]]
:❑ Intravenous inotropic drugs ([[dobutamine]])
:❑ Intravenous inotropic drugs ([[dobutamine]])
:❑ [[Diuretic]]therapy  
:❑ [[Diuretic]] therapy  
:❑ IV [[vasodilators]]
:❑ IV [[vasodilators]]
</div>| A02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''CAD treatment''': <br>
</div>| A02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Coronary artery disease:''' <br>
❑ Click [[Chronic stable angina medical therapy|here]] for [[coronary artery disease]] medical therapy
❑ Click [[Chronic stable angina medical therapy|here]] for [[coronary artery disease]] medical therapy
:❑ [[Aspirin]]
:❑ [[Aspirin]]
Line 694: Line 693:
❑ [[Coronary angiography]] <br>
❑ [[Coronary angiography]] <br>
❑ Click [[Chronic stable angina revascularization|here]] for [[revascularization]] therapy <br>
❑ Click [[Chronic stable angina revascularization|here]] for [[revascularization]] therapy <br>
</div>| A03=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Cardiac resynchronization therapy''': <br>
</div>| A03=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Functional [[MR]] with ventricular dyssynchrony:'''<br>
❑ [[Cardiac resynchronization therapy]] with biventricular pacing:
❑ [[Cardiac resynchronization therapy]] with biventricular pacing:
:❑ In functional [[MR]] patients with ventricular dyssynchrony
:❑ To reduce LV end-systolic and end-diastolic dimensions  
:❑ Reduce LV end-systolic and end-diastolic dimensions  
:❑ To reduce mitral regurgitant jet area  
:❑ Reduce mitral regurgitant jet area  
</div>}}
</div>}}
{{familytree | | | |`|-|-|-|+|-|-|-|'| | | | | | | | | | | | | | }}
{{familytree | | | |`|-|-|-|+|-|-|-|'| | | | | | | | | | | | | | }}
{{familytree | | | | | | | A01 | | | | | A01=Assess the severity of [[MR]] on [[TTE]]}}
{{familytree | | | | |,|-|-|^|-|-|.| | | | | | | | | | | | | | | }}
{{familytree | | | | |,|-|-|^|-|-|.| | | | | | | | | | | | | | | }}
{{familytree | | | | A01 | | | | A02 | | | | | | | | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Severe [[MR]]''': <br>
{{familytree | | | | A01 | | | | A02 | | | | | | | | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Severe [[MR]]''': <br>
❑ Echo findings:
❑ Regional wall motion abnormalities with severe tethering of mitral leaflet<br>
:❑ Regional wall motion abnormalities with severe tethering of mitral leaflet
❑ Annular dilation with severe loss of central coaptation of the mitral leaflets<br>
:❑ Annular dilation with severe loss of central coaptation of the mitral leaflets
❑ LV dilation and [[systolic dysfunction]] due to primary myocardial disease<br>
❑ LV dilation and [[systolic dysfunction]] due to primary myocardial disease<br>
❑ Regurgitation fraction ≥ 50%<br>
❑ Regurgitation fraction ≥ 50%<br>
❑ Regurgitation volume ≥ 30ml<br>
❑ Regurgitation volume ≥ 30ml<br>
❑ Effective regurgitation orifice ≥ 0.2 cm²<br>
❑ Effective regurgitation orifice ≥ 0.2 cm²<br>
</div>| A02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Progressive [[MR]]''' (Stage B): <br>
</div>| A02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Progressive [[MR]]:''' <br>
❑ Echo findings:
❑ Regional wall motion abnormalities with mild tethering of mitral leaflets<br>
:❑ Regional wall motion abnormalities with mild tethering of mitral leaflet
❑ Annular dilation with mild loss of central coaptation of the mitral leaflets<br>
:❑ Annular dilation with mild loss of central coaptation of the mitral leaflets
❑ LV dilation and [[systolic dysfunction]] due to primary myocardial disease<br>
❑ LV dilation and [[systolic dysfunction]] due to primary myocardial disease<br>
❑ Regurgitation fraction < 50%<br>
❑ Regurgitation fraction < 50%<br>
Line 719: Line 716:
❑ Effective regurgitation orifice < 0.2 cm²<br>
❑ Effective regurgitation orifice < 0.2 cm²<br>
</div>}}
</div>}}
{{familytree | | | | |!| | | | | |!| | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | A01 | | | | A02 | | | | | | | | | | | | | | | | | | | | | A01= '''Does the [[HF]] symptoms due to [[MR]] persist even after [[revascularization]] and medical therapy?'''|A02=[[HF]] and [[coronary ischemia]] symptoms respond to [[revascularization]] and medical herapy}}
{{familytree | | |,|-|^|-|.| | | |!| | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | |,|-|^|-|.| | | |!| | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | | | | | | | | A01=Stage D: Symptomatic ([[HF]] symptoms due to [[MR]] persist even after [[revascularization]] and medical therapy) | A02= Stage C: Asymptomatic ([[HF]] and [[coronary ischemia]] symptoms respond to [[revascularization]] and medical herapy)| A03= [[HF]] and [[coronary ischemia]] symptoms respond to [[revascularization]] and medical herapy}}
{{familytree | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | | | | | | | | A01= Yes ('''Stage D''')| A02= No ('''Stage C''')| A03= '''Stage B'''}}
{{familytree | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Mitral valve surgery:'''<br>
{{familytree | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Perform mitral valve surgery:'''<br>
----
❑ [[Mitral valve repair]]: <br>
❑ [[Mitral valve repair]]: <br>
:❑ Mostly preferred
:❑ Mostly preferred
❑ [[Mitral valve replacement]]:
❑ [[Mitral valve replacement]]:
:❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
----
'''Anticoagulation therapy:'''<br>
----
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ History of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ Recurrent [[embolism]] despite adequate [[anticoagulation]]
----
'''Endocarditis prophylaxis:'''<br>
----
❑ [[Endocarditis antimicrobial treatment|Initiate infective endocarditis antimicrobial prophylaxis]]<br>
</div>|A02=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Periodic monitoring:'''<br>
</div>|A02=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Periodic monitoring:'''<br>
----
❑ Clinical evaluation:
❑ Clinical evaluation:
:❑ Every 3-6 months
:❑ Every 3-6 months
Line 751: Line 734:
:❑ Every 6 months
:❑ Every 6 months
----
----
'''Mitral valve surgery:'''<br>
'''Consider mitral valve surgery:'''<br>
----
❑ Only for patients undergoing other [[cardiac surgery]]<br>
❑ Only in patients undergoing other [[cardiac surgery]]<br>
❑ [[Mitral valve repair]]: <br>
:❑ Mostly preferred
❑ [[Mitral valve replacement]]:
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
----
'''Anticoagulation therapy:'''<br>
----
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ History of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ Recurrent [[embolism]] despite adequate [[anticoagulation]]
----
'''Endocarditis prophylaxis:'''<br>
----
❑ [[Endocarditis antimicrobial treatment|Initiate infective endocarditis antimicrobial prophylaxis for patients undergoing mitral valve surgery]]<br>
</div>| A03=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Periodic monitoring:'''<br>
</div>| A03=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Periodic monitoring:'''<br>
----
❑ Clinical evaluation:
❑ Clinical evaluation:
:❑ Every 3-6 months
:❑ Every 3-6 months
Line 781: Line 742:
:❑ Every 6 months
:❑ Every 6 months
----
----
'''Mitral valve surgery:'''<br>
'''Consider mitral valve surgery:'''<br>
----
❑ Only for patients undergoing other [[cardiac surgery]]<br>
❑ Only in patients undergoing other [[cardiac surgery]]<br>
</div>}}
❑ [[Mitral valve repair]]: <br>
{{familytree | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | | | | | | }}
:❑ Mostly preferred
{{familytree | | A01 | | A02 | | A03 | | | | | | | | | | | | | | | | | | | | | | A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
❑ [[Mitral valve replacement]]:
❑ Indications:
:❑ [[Mechanical valve]] in patients <65 years who have long-standing [[AF]]
:History of systemic [[embolism]]
:❑ [[Bioprosthetic valves]] in patients with contraindications to [[warfarin]]
:❑ Left atrial thrombus
----
:❑ Paroxysmal or chronic [[atrial fibrillation]]
'''Anticoagulation therapy:'''<br>
:❑ [[Mitral valve replacement]]
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Target INR 3 (for [[prosthetic valve]])
[[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ For patients with recurrent [[embolism]] despite adequate [[anticoagulation]]
:❑ For patients with [[prosthetic valve]]
----
----
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
❑ For patients who undergo [[mitral valve replacement]]<br>
❑ Indicated for the following procedures:
:❑ [[Endocarditis antibiotic prophylaxis#Basis for AHA Recommendations Regarding Antibiotic Prophylaxis for Dental Procedures|Dental procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis For Respiratory Tract Procedures|Respiratory tract procedures]]
:❑ [[Endocarditis antibiotic prophylaxis#Antibiotic Prophylaxis for Gastrointestinal (GI) and Genitourinary (GU) Procedures|GI and GU procedures]]
</div>|A02=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
❑ Indications:
:❑ History of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]
❑ [[Warfarin]]:
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
:❑ Target INR 2.5 (range 2.0 to 3.0)
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ For patients with recurrent [[embolism]] despite adequate [[anticoagulation]]
----
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
❑ Only if they undergo [[mitral valve replacement]]<br>
</div>| A03=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate anticoagulation therapy:'''<br>
❑ Indications:
:❑ History of systemic [[embolism]]
:❑ History of systemic [[embolism]]
:❑ Left atrial thrombus
:❑ Left atrial thrombus
:❑ Paroxysmal or chronic [[atrial fibrillation]]  
:❑ Paroxysmal or chronic [[atrial fibrillation]]
❑ [[Warfarin]]:
:❑ Target INR 2.5 (range 2.0 to 3.0)
❑ [[Aspirin]]: <br>
❑ [[Aspirin]]: <br>
:❑ 75 to 100 mg/day
:❑ 75 to 100 mg/day
:❑ Recurrent [[embolism]] despite adequate [[anticoagulation]]
:❑ For patients with recurrent [[embolism]] despite adequate [[anticoagulation]]
----
'''Endocarditis prophylaxis:'''<br>
----
----
[[Endocarditis antimicrobial treatment|Initiate infective endocarditis antimicrobial prophylaxis for patients undergoing mitral valve surgery]]<br>
'''Educate the patient about [[Endocarditis antibiotic prophylaxis|IE prophylaxis]]:'''<br>
</div>}}
❑ Only if they undergo [[mitral valve replacement]]<br>
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
</div>}}  
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}


Line 816: Line 802:


==Don'ts==
==Don'ts==
* Don't initiate [[vasodilator therapy]] for normotensive asymptomatic patients with chronic primary [[MR]] (stages B and C1) and normal systolic LV function.
* Don't initiate [[vasodilator]] therapy for normotensive asymptomatic patients with chronic primary [[MR]] (stages B and C1) and normal systolic LV function.
* Don't recommend cardiovascular magnetic resonance (CMR) for routine diagnosis of [[MR]].
* Don't recommend cardiovascular magnetic resonance (CMR) for routine diagnosis of [[MR]].
* Don't prefer [[mitral valve repair]] to replacement to chronic severe primary [[MR]] patients involving the anterior leaflet or both leaflets when a successful and durable repair cannot be accomplished.  
* Don't prefer [[mitral valve repair]] to replacement to chronic severe primary [[MR]] patients involving the anterior leaflet or both leaflets when a successful and durable repair cannot be accomplished.  

Latest revision as of 13:57, 19 May 2015


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]

Mitral Regurgitation Resident Survival Guide Microchapters
Overview
Causes
FIRE
Complete Diagnostic Approach
Treatment
Acute MR
Chronic MR
Do's
Don'ts

Overview

Mitral regurgitation (MR) is a disorder of the heart characterized by failure of the mitral valve to close properly during systole leading to blood leakage from the left ventricle to the left atrium during systole. Individuals with acute mitral regurgitation may present with significant hemodynamic instability due to the sudden drop in cardiac output, leading to acute pulmonary edema, hypotension and possible cardiogenic shock. Individuals with chronic compensated mitral regurgitation may be asymptomatic, with a normal exercise tolerance and no evidence of heart failure, or may present with fatigue, dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea.[1] The management of MR includes afterload reduction with careful monitoring of fluid status, management of the underlying disease (CAD, mitral valve prolapse, rheumatic heart disease), and early surgical intervention in severe cases. Ultimately, the management of MR depends on the anatomy of the mitral valve, the acuteness of the disease process, and the severity of presentation. [2]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Acute Mitral Regurgitation

Chronic Primary Mitral Regurgitation

Chronic Secondary Mitral Regurgitation

Click here for the complete list of causes.

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.

Boxes in red color signify that an urgent management is needed. Abbreviations: ARBs: Angiotensin II receptor antagonist; CABG: Coronary artery bypass surgery; HF: Heart failure; IE: Infective endocarditis; LVEF: Left ventricular ejection fraction; LV: Left ventricle; MR: Mitral regurgitation; S1: First heart sound; S2: Second heart sound

 
 
 
 
 
 
 
 
Identify cardinal findings that increase the pretest probability of mitral regurgitation:

Murmur:

❑ Soft, low pitched and decrescendo (in acute MR due to diminished pressure gradient between the left atrium and ventricle)
❑ High pitched and blowing holosystolic murmur best heard over the apex radiating to the axilla and back
❑ Silent (in acute ischemic MR)

Heart sounds:

S1 is diminished (typical)
❑ Wide splitting of S2 (low forward flow causing early A2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any of the following findings of acute mitral regurgitation with instability?

❑ Sudden onset and rapid progression of pulmonary edema:

Shortness of breath
Tachypnea
Crackles or rales

Signs and symptoms of cardiogenic shock:

Tachycardia
Hypotension
Altered mental status
Oliguria
Diaphoresis
Cold extremities
Peripheral cyanosis
Mottling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continue with complete diagnostic approach below
 
 
 
 
 
 
 
 
 
 
Initiate resuscitative measures:

❑ Secure airway
❑ Administer O2
❑ Establish 2 wide bore IV access
❑ Establish an arterial line
❑ Connect to ECG monitor
❑ Monitor vitals continuously
❑ Consider ICU admission
❑ Consider mechanical ventilation
❑ Consider pulmonary artery catheterization


Order imaging and blood tests (urgent):
Transthoracic echocardiography (TTE)
Chest X-ray
CBC
Serum electrolytes
Blood cultures (in case of fever)
❑ Serum cardiac troponin I and T
Creatine kinase (CK-MB)
❑ Serum urea and creatinine

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has any evidence of MR in TTE?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Stabilize the patient:
❑ Initiate medical stabilization:

Vasodilator (IV nitroprusside) PLUS inotropic agents (IV dobutamine)

❑ Establish intra-aortic balloon pump:

❑ If medical therapy is not effective to maintain hemodynamic stability

Initiate treatment for specific etiologies:
Aspirin in case of myocardial infarction
❑ Antibiotics in case of infective endocarditis

 
Consider other possible diagnosis:

Acute respiratory distress syndromeSepsis

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any findings on TTE that require mitral valve surgery?

❑ Flail mitral leaflet (papillary muscle or chordal rupture)
❑ Any signs of endocarditis

❑ Vegetations on the leaflets
❑ Paravalvular abscess
❑ Moderate to severe ischemic MR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform mitral valve surgery:

Mitral valve repair:

❑ Most preferred
❑ Done in absence of papillary muscle necrosis

Mitral valve replacement:

❑ Performed in cases of complex MR with extensive tissue destruction
❑ Performed in cases of MR with lateral LV wall motion abnormality
 
Perform reperfusion or revascularization:

❑ In patients with acute coronary syndrome, CABG or coronary angioplasty should be performed
❑ Early reperfusion for myocardial infarction can reduce localized LV remodeling and hence MR

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform reperfusion or revascularization:

❑ Perform CABG or coronary angioplasty at the time of mitral valve surgery in patients with myocardial infarction


Consider cardiac transplantation:
❑ On some occasions with no contraindication for surgery
❑ For patients with severe LV dysfunction

 
 
 
 
 

Complete Diagnostic Approach to Mitral Regurgitation

A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[2].
Abbreviations: AF: Atrial fibrillation; MR: Mitral regurgitation; EKG: Electrocardiogram; EF: Ejection fraction; S1: First heart sound; S2: Second heart sound; S3: Third heart sound; LV: Left ventricle; MVP: Mitral valve prolapse

 
 
 
 
 
 
Characterize the symptoms:

Acute mitral regurgitation:Symptoms of shock and pulmonary edema:

Shortness of breath
Orthopnea
Paroxysmal nocturnal dyspnea
Cough
Altered mental status
Pedel edema
Oliguria
Cyanosis
Pallor
Diaphoresis
Abdominal pain (may be suggestive of mesenteric ischemia)

Symptoms suggestive of precipitating events:

Chest pain (suggestive of myocardial ischemia)
Fever (suggestive of infective endocarditis)
Petechiae, Osler's nodes, Janeway lesions (suggestive of infective endocarditis)

Chronic mitral regurgitation:Asymptomatic

❑ Typical in isolated mild to moderate MR
❑ Severe MR until there is left ventricular failure, pulmonary hypertension or atrial fibrillation

Symptoms associated with decreased forward flow and increased backflow across mitral valve (left ventricular failure):

Exertional dyspnea
Orthopnea
Paroxysmal nocturnal dyspnea
Exercise intolerance
Fatigue
Light-headedness
Exertional syncope
Exertional angina
Cough

Symptoms associated with complications:

Palpitations (suggestive of atrial fibrillation)
Hoarseness (recurrent laryngeal nerve compression due to left atrium enlargement)
Fever (suggestive of infective endocarditis)
Stroke (suggestive of thromboembolism)
Hemoptysis (suggestive of thromboembolism)
Flank pain and hematuria (suggestive of septic emboli or glomerulonephritis)
Seizures (suggestive of thromboembolism)
❑ Symptoms of right heart failure:
Ascites
Pedel edema
Abdominal pain (hepatomegaly)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

Vital signs:
Pulse

❑ Rapid and thready (in acute MR)
❑ Low volume with brisk upstroke (in chronic MR)
Irregularly irregular pulse (with onset of AF)

Blood pressure

Hypotension (in acute MR)
❑ Normotensive (in chronic MR with preserved ejection fraction)

Temperature

Fever (suggestive of infective endocarditis)

Respiratory rate

Tachypnea (typical)

Skin:
❑ Cool and clammy (in cardiogenic shock)
Cyanosis
Peripheral edema (suggestive of right heart failure)

Cardiovascular system:
Palpation:
Apical impulse

❑ Leftward displacement (in chronic MR due enlargement of the left ventricle)
❑ Hyperdynamic but in normal location (in acute MR)

Thrill (in acute MR and severe chronic MR)
❑ Elevated jugular venous pulse

❑ Sign of elevated right sided pressure
❑ Seen in acute MR and severe chronic MR

Auscultation:
❑ Heart sounds

S1 is diminished (suggestive of MR)
❑ Wide splitting of S2 (low forward flow causing early A2)
❑ Loud and delayed P2 (suggestive of pulmonary hypertension)
❑ New S3 (suggestive of left ventricular dilation)

Murmur

❑ High pitched and blowing holosystolic murmur (typical)
❑ Best heard over the apex radiating to the axilla and back
❑ Starts after S1 and continues up to and sometime beyond and obscuring A2
❑ Other types of murmur
❑ Silent (in cases of acute MR)
❑ Mid to late systolic murmur (in case of papillary muscle prolapse)
❑ Early diastolic murmur (due to large diastolic flow across severe MR)
❑ Mid systolic click (suggestive of mitral valve prolapse)

Respiratory system:
Crackles or rales (suggestive of pulmonary edema)
Tachypnea

Abdominal system:
❑ Hepatojugular reflex
Hepatomegaly
Ascites

Neurological system:
Stroke (in case of thromboembolism)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order electrocardiogram (urgent):

❑ In acute MR

❑ Mostly normal
❑ Findings of myocardial infarction

❑ In chronic MR

❑ Findings of left ventricular hypertrophy with strain
❑ Findings of left atrial enlargement
❑ Findings of pulmonary hypertension
❑ Findings of atrial fibrillation complication
Left atrial enlargement produces a broad, bifid P wave in lead II (P mitrale)

Order chest X-ray (urgent):
Acute MR

❑ Normal size cardiac silhouette
❑ Signs of pulmonary edema

Chronic MR

Cardiomegaly
❑ Signs of pulmonary edema if left ventricle fails
❑ Calcification of the mitral valve annulus
Calcification of the mitral annulus around the margins of the posterior leaflet forming a “C”

Order transthoracic echocardiography (TTE) (urgent):
❑ Confirmatory
❑ To determine severity and assess hemodynamic consequences
❑ To establish etiology
❑ To determine prognosis and evaluate for timing of intervention

Order lab tests:
CBC
Electrolytes
ESR
Serum cardiac troponin I and T
Creatine kinase (CK-MB)
Blood cultures (in case of fever)
❑ Serum urea and creatinine

Other tests:
Transesophageal echocardiography (TEE if TTE is equivocal)
Cardiac catheterization:

❑ In stable acute MR to detect coronary obstruction
❑ To assess hemodynamic status in symptomatic patients when noninvasive tests are inconclusive
❑ To assess the severity when there is discrepancy between noninvasive testing and physical examination

❑ Exercise testing:

❑ Done in asymptomatic severe MR
❑ To confirm the absence of symptoms
❑ To assess the hemodynamic response to exercise

Cardiac MRI

❑ To assess severity when there is a discrepancy between clinical findings and echocardiography
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has acute or chronic MR?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute MR (Cardinal findings suggestive of acute mitral regurgitation)

❑ Sudden onset and rapid progression of pulmonary edema
Signs and symptoms of cardiogenic shock
❑ Silent to holosystolic murmur on auscultation
❑ Normal ECG
❑ Normal size cardiac silhouette on chest X-ray
Echocardiography findings:

❑ Acute severe mitral regurgitation
❑ Normal left ventricular size
❑ Reduced EF
❑ Ruptured mitral chordae tendinae (flail leaflet)
❑ Ruptured papillary muscle
 
 
 
 
 
Chronic MR (cardinal findings suggestive of chronic mitral regurgitation)

❑ Asymptomatic to chronic symptoms
❑ Pre-existing heart disease
❑ Classic holosystolic murmur on auscultation
ECG findings of left ventricular hypertrophy with strain and left atrial enlargement
Cardiomegaly on chest X-ray
Echocardiography findings:

Mitral regurgitation
Left ventricular dilation
❑ Preserved to decreased EF
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the mitral valve anatomy appear normal in TTE?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic secondary mitral regurgitation
 
Chronic primary mitral regurgitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Treatment

Treatment of Acute Mitral Regurgitation

Shown below is an algorithm summarizing the approach to the management of acute mitral regurgitation.[1][2].
Abbreviations: IE: Infective endocarditis; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MR: Mitral regurgitation

 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has any signs of hemodynamic instability?

Hypotension
Cold extremities
Peripheral cyanosis
Altered mental status

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate resuscitative measures:

❑ Secure airway
❑ Administer O2
❑ Establish 2 wide bore IV access
❑ Establish an arterial line
❑ Connect to ECG monitor
❑ Monitor vitals continuously
❑ Consider ICU admission
❑ Consider mechanical ventilation
❑ Consider pulmonary artery catheterization


Stabilize the patient:
❑ Initiate medical stabilization:

Vasodilator (IV nitroprusside) PLUS inotropic agents (IV dobutamine)

❑ Establish intra-aortic balloon pump:

❑ If medical therapy is not effective to maintain hemodynamic stability
 
 
 
Initiate resuscitative measures:

❑ Administer O2
❑ Establish 2 wide bore IV access
❑ Connect to ECG monitor
❑ Monitor vitals continuously


Initiate medical therapy:

Vasodilator therapy: IV nitroprusside
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MR due to IE (organic MR)
 
 
 
 
 
Ischemic mitral regurgitation
 
 
 
 
 
MR due to heart failure exacerbation(functional MR)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Initiate IE medical therapy:


❑ Click here for infective endocarditis resident survival guide and antimicrobial treatment

 
 
 
 
 
Perform reperfusion or revascularization surgery:

CABG or coronary angioplasty should be done to treat acute coronary syndrome
❑ Early reperfusion can reduce localized LV remodeling and hence MR

 
 
 
 
 
Initiate treatment for heart failure:

❑ Click here for acute heart failure resident survival guide

ACE inhibitors or (ARBs) if LVEF is ≤ 40%
Beta blockers
❑ Intravenous inotropic drugs (dobutamine)
Diuretic therapy
❑ IV vasodilators
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has any indications for mitral valve surgery?

❑ Hemodynamic instability
❑ Persistent heart failure
Pulmonary hypertension

❑ Early mitral valve closure
 
 
 
 
 
Does the patient has any indications for mitral valve surgery?

Papillary muscle rupture
Chordae tendinae rupture

❑ Moderate to severe ischemic MR who are undergoing CABG
 
 
 
 
 
Does the patient show any hemodynamic improvement to medical therapy?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
Yes
 
No
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform mitral valve surgery:

Mitral valve replacement:

❑ Mostly done
❑ Due to extensive tissue destruction in IE patients

Mitral valve repair:

❑ If less mitral valve destruction
 
❑ Continue with medical management
 
Perform mitral valve surgery:

❑ Done at the time of reperfusion
Mitral valve repair:

❑ Most preferred

Mitral valve replacement: Preferred in the following groups

❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
❑ Very ill patients presenting after an acute MI
❑ Complex MR
❑ In cases of lateral LV wall motion abnormality
 

Consider medical therapy:
❑ In cases of reduced LVEF (ischemic cardiomyopathy)
❑ Medications:

Angiotensin converting enzyme inhibitors
Angiotensin II receptor blockers
Beta blockers

Consider cardiac transplantation:
❑ On some occasions in patients with severe LV dysfunction with no contraindication for surgery

 
Continue with the heart failure management and have appropriate follow ups to assess the severity of MR
 
Consider mitral valve surgery:

Mitral valve repair:

❑ Most preferred

Mitral valve replacement:

❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
❑ In cases of lateral LV wall motion abnormality
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate anticoagulation therapy:

❑ For patients undergoing mitral valve replacement
Warfarin: Target INR 3
Aspirin: 75 to 100 mg/day


Educate the patient about IE prophylaxis:
❑ For all patients
❑ Indicated for the following procedures:

Dental procedures
Respiratory tract procedures
GI and GU procedures
 
 
 
Initiate anticoagulation therapy:

❑ For patients undergoing mitral valve replacement
Warfarin: Target INR 3
Aspirin: 75 to 100 mg/day


Educate the patient about IE prophylaxis:
❑ For patients who undergo mitral valve replacement
❑ Indicated for the following procedures:

Dental procedures
Respiratory tract procedures
GI and GU procedures
 
 
 
 
 
 
 
 
 
Initiate anticoagulation therapy:

❑ For patients undergoing mitral valve replacement
Warfarin: Target INR 3
Aspirin: 75 to 100 mg/day


Educate the patient about IE prophylaxis:
❑ For patients who undergo mitral valve replacement
❑ Indicated for the following procedures:

Dental procedures
Respiratory tract procedures
GI and GU procedures
 
 
 
 
 
 
 
 
 
 
 

Treatment of Chronic Mitral Regurgitation

Chronic Primary Mitral Regurgitation

Shown below is an algorithm summarizing the approach to the management of chronic primary mitral regurgitation.[2].
Abbreviations: AF: Atrial fibrillation; IE: Infective endocarditis; LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end systolic dimension; MR: Mitral regurgitation; MVP: Mitral valve proplapse; PASP: Pulmonary artery systolic pressure; RHD: Rheumatic heart disease

 
 
 
 
 
 
 
 
Determine the severity of MR on TTE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe MR:

❑ Severe MVP with loss of coaptation
RHD with loss of central coaptation
Left ventricular dilation
❑ Regurgitation fraction ≥ 50%
❑ Regurgitation volume ≥ 60ml
❑ Effective regurgitation orifice ≥ 0.4cm²
❑ Vena contracta ≥ 0.7cm

 
 
 
 
 
 
 
Progressive MR (Stage B):

❑ Severe MVP with normal coaptation
RHD with normal coaptation
❑ No Left ventricular dilation
❑ Regurgitation fraction < 50%
❑ Regurgitation volume < 60ml
❑ Effective regurgitation orifice < 0.4cm²
❑ Vena contracta < 0.7cm

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptomatic (Stage D)
 
 
 
Asymptomatic (Stage C)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has any indications for mitral valve surgery?

LVEF 30 to ≤60% OR LVESD ≥ 40mm (Stage C2)
LVEF >60% AND LVESD < 40mm (Stage C1)

❑ With likelihood of successful repair > 95%
❑ With expected mortality < 1%

❑ New onset AF OR PASP > 50mmHg (Stage C1)

❑ With likelihood of successful repair > 95%
❑ With expected mortality < 1%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate medical therapy:

Vasodialators:

❑ Intravenous nitroprusside
Hydralazine

Beta blocker
Diuretics
Calcium channel blocker


Perform mitral valve surgery:
Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Perform revascularisation:
❑ In cases with concurrent coronary artery disease
❑ Revascularized at the time of mitral valve surgery

 
Perform mitral valve surgery:

Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin

Perform revascularization:
❑ For patients with concurrent coronary artery disease
❑ Revascularized at the time of mitral valve surgery

 

Periodic monitoring:
❑ In stage C1 patients with the following:

❑ With likelihood of successful repair < 95%
❑ With expected mortality > 1%

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months
 
Periodic monitoring:

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate anticoagulation therapy:

❑ Indications:

❑ Rheumatic mitral valve disease who have a history of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation
Mitral valve replacement

Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Target INR 3 (for prosthetic valve)

Aspirin:

❑ 75 to 100 mg/day
❑ For patients with recurrent embolism despite adequate anticoagulation
❑ For patients with prosthetic valve

Educate the patient about IE prophylaxis:
❑ For patients who undergo mitral valve replacement
❑ Indicated for the following procedures:

Dental procedures
Respiratory tract procedures
GI and GU procedures
 
 
 
Initiate anticoagulation therapy:

❑ Indications:

❑ Rheumatic mitral valve disease who have a history of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation
Mitral valve replacement

Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Target INR 3 (for prosthetic valve)

Aspirin:

❑ 75 to 100 mg/day
❑ For patients with recurrent embolism despite adequate anticoagulation
❑ For patients with prosthetic valve

Educate the patient about IE prophylaxis:
❑ For patients who undergo mitral valve replacement
❑ Indicated for the following procedures:

Dental procedures
Respiratory tract procedures
GI and GU procedures
 
 
 
Initiate anticoagulation therapy:

❑ Indications:

❑ Rheumatic mitral valve disease who have a history of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation
Mitral valve replacement

Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Target INR 3 (for prosthetic valve)

Aspirin:

❑ 75 to 100 mg/day
❑ For patients with recurrent embolism despite adequate anticoagulation
❑ For patients with prosthetic valve
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Chronic Secondary Mitral Regurgitation

Shown below is an algorithm summarizing the approach to the management of chronic secondary mitral regurgitation.[2].

Abbreviations: AF: Atrial fibrillation; CAD: Coronary artery disease; HF: Heart failure; IE: Infective endocarditis; LV: Left ventricle; MR: Mitral regurgitation

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determine the etiology and initiate specific treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart failure:

❑ Click here for heart failure resident survival guide

ACE inhibitors
ARBs
Beta blockers
❑ Intravenous inotropic drugs (dobutamine)
Diuretic therapy
❑ IV vasodilators
 
Coronary artery disease:

❑ Click here for coronary artery disease medical therapy

Aspirin
ACE inhibitors
Beta blockers

Coronary angiography
❑ Click here for revascularization therapy

 
Functional MR with ventricular dyssynchrony:

Cardiac resynchronization therapy with biventricular pacing:

❑ To reduce LV end-systolic and end-diastolic dimensions
❑ To reduce mitral regurgitant jet area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess the severity of MR on TTE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe MR:

❑ Regional wall motion abnormalities with severe tethering of mitral leaflet
❑ Annular dilation with severe loss of central coaptation of the mitral leaflets
❑ LV dilation and systolic dysfunction due to primary myocardial disease
❑ Regurgitation fraction ≥ 50%
❑ Regurgitation volume ≥ 30ml
❑ Effective regurgitation orifice ≥ 0.2 cm²

 
 
 
Progressive MR:

❑ Regional wall motion abnormalities with mild tethering of mitral leaflets
❑ Annular dilation with mild loss of central coaptation of the mitral leaflets
❑ LV dilation and systolic dysfunction due to primary myocardial disease
❑ Regurgitation fraction < 50%
❑ Regurgitation volume < 30ml
❑ Effective regurgitation orifice < 0.2 cm²

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the HF symptoms due to MR persist even after revascularization and medical therapy?
 
 
 
HF and coronary ischemia symptoms respond to revascularization and medical herapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes (Stage D)
 
No (Stage C)
 
Stage B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform mitral valve surgery:

Mitral valve repair:

❑ Mostly preferred

Mitral valve replacement:

❑ In centers with surgeons who do not have expertise in mitral valve repair techniques
Mechanical valve in patients <65 years who have long-standing AF
Bioprosthetic valves in patients with contraindications to warfarin
 
Periodic monitoring:

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months

Consider mitral valve surgery:
❑ Only for patients undergoing other cardiac surgery

 
Periodic monitoring:

❑ Clinical evaluation:

❑ Every 3-6 months

Echocardiography:

❑ Every 6 months

Consider mitral valve surgery:
❑ Only for patients undergoing other cardiac surgery

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate anticoagulation therapy:

❑ Indications:

❑ History of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation
Mitral valve replacement

Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)
❑ Target INR 3 (for prosthetic valve)

Aspirin:

❑ 75 to 100 mg/day
❑ For patients with recurrent embolism despite adequate anticoagulation
❑ For patients with prosthetic valve

Educate the patient about IE prophylaxis:
❑ For patients who undergo mitral valve replacement
❑ Indicated for the following procedures:

Dental procedures
Respiratory tract procedures
GI and GU procedures
 
Initiate anticoagulation therapy:

❑ Indications:

❑ History of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)

Aspirin:

❑ 75 to 100 mg/day
❑ For patients with recurrent embolism despite adequate anticoagulation

Educate the patient about IE prophylaxis:
❑ Only if they undergo mitral valve replacement

 
Initiate anticoagulation therapy:

❑ Indications:

❑ History of systemic embolism
❑ Left atrial thrombus
❑ Paroxysmal or chronic atrial fibrillation

Warfarin:

❑ Target INR 2.5 (range 2.0 to 3.0)

Aspirin:

❑ 75 to 100 mg/day
❑ For patients with recurrent embolism despite adequate anticoagulation

Educate the patient about IE prophylaxis:
❑ Only if they undergo mitral valve replacement

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Do's

  • Always consult a multidisciplinary heart valve team for patients with acute MR, severe chronic MR and with multiple comorbidities.
  • Consider vasodilator therapy in patients with chronic MR based upon the presence or absence of symptoms and the functional state of the left ventricle.
  • Always consider patients with chronic MR who become symptomatic to be candidates for corrective mitral surgery.
  • Perform mitral valve repair for patients with chronic severe primary MR limited to the posterior leaflet.

Don'ts

  • Don't initiate vasodilator therapy for normotensive asymptomatic patients with chronic primary MR (stages B and C1) and normal systolic LV function.
  • Don't recommend cardiovascular magnetic resonance (CMR) for routine diagnosis of MR.
  • Don't prefer mitral valve repair to replacement to chronic severe primary MR patients involving the anterior leaflet or both leaflets when a successful and durable repair cannot be accomplished.
  • Don't perform mitral valve replacement in patients with isolated severe primary MR limited to less than one half of the posterior leaflet unless mitral valve repair has been attempted and was unsuccessful.
  • Don't perform coronary angiography before valve surgery in patients who are hemodynamically unstable.
  • Avoid coronary angiography in patients of acute coronary syndrome complicated by severe acute mitral regurgitation.

References

  1. 1.0 1.1 Stout KK, Verrier ED (2009). "Acute valvular regurgitation". Circulation. 119 (25): 3232–41. doi:10.1161/CIRCULATIONAHA.108.782292. PMID 19564568.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.
  3. Anderson Y, Wilson N, Nicholson R, Finucane K (2008). "Fulminant mitral regurgitation due to ruptured chordae tendinae in acute rheumatic fever". J Paediatr Child Health. 44 (3): 134–7. doi:10.1111/j.1440-1754.2007.01214.x. PMID 17854408.
  4. Grinberg AR, Finkielman JD, Piñeiro D, Festa H, Cazenave C (1998). "Rupture of mitral chorda tendinea following blunt chest trauma". Clin Cardiol. 21 (4): 300–1. PMID 9580528.
  5. Grenadier E, Alpan G, Keidar S, Palant A (1983). "The prevalence of ruptured chordae tendineae in the mitral valve prolapse syndrome". Am Heart J. 105 (4): 603–10. PMID 6837414.
  6. Otto CM (2001). "Clinical practice. Evaluation and management of chronic mitral regurgitation". N Engl J Med. 345 (10): 740–6. doi:10.1056/NEJMcp003331. PMID 11547744.


Template:WikiDoc Sources